Xeljanz® (tofacitinib) – New indication, new formulation
September 28, 2020 - Pfizer announced the FDA approval of Xeljanz (tofacitinib), for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older.
Download PDF
